NCT06414135View on ClinicalTrials.gov

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

April 30, 2027

Conditions
Systemic Sclerosis
Interventions
BIOLOGICAL

Relma-cel

All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells

Trial Locations (1)

200001

RECRUITING

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY

lead

Liangjing Lu

OTHER